Dr Reddy's Q1 Profit Down 1% to Rs 1,392 Cr
By Rediff Money Desk, Hyderabad Jul 27, 2024 18:59
Dr Reddy's Laboratories reported a 1% decline in consolidated profit after tax to Rs 1,392 crore in the June quarter, driven by growth in generics business. Revenues rose 14% to Rs 7,673 crore.
Hyderabad, Jul 27 (PTI) Dr Reddy's Laboratories Ltd on Saturday said its consolidated profit after tax for the quarter ended June 30 was down by one per cent to Rs 1,392 crore compared to Rs 1,403 crore during the same period last fiscal.
A press release from the city-based drugmaker said revenues for the quarter under discussion was up by 14 per cent to Rs 7,673 crore. It was Rs 6,738 crore during the first quarter of FY 24.
Commenting on the results, Co-Chairman and MD, G V Prasad said the firm had a good start to the new fiscal year and the growth and profitability were mainly driven by our generics business.
"We continue to strengthen our core businesses and have made strategic investments in biologics, consumer healthcare and innovation to drive patient impact and value creation," Prasad said.
Revenues from North America grew at 20 per cent to Rs 3,850 crore largely on account of increase in volumes of base business, contribution from new launches, partly offset by price erosion.
Europe revenues were at Rs 530 crore, a year on year growth of four per cent while Indian income stood at Rs 1330 crore registering a growth of 15 per cent during the quarter.
With three per cent growth emerging markets reported Rs 1,190 crore.
Revenues from Pharmaceutical Services and Active Ingredients stood at Rs 770 crore (14 per cent Y-o-Y growth) during the first quarter.
A press release from the city-based drugmaker said revenues for the quarter under discussion was up by 14 per cent to Rs 7,673 crore. It was Rs 6,738 crore during the first quarter of FY 24.
Commenting on the results, Co-Chairman and MD, G V Prasad said the firm had a good start to the new fiscal year and the growth and profitability were mainly driven by our generics business.
"We continue to strengthen our core businesses and have made strategic investments in biologics, consumer healthcare and innovation to drive patient impact and value creation," Prasad said.
Revenues from North America grew at 20 per cent to Rs 3,850 crore largely on account of increase in volumes of base business, contribution from new launches, partly offset by price erosion.
Europe revenues were at Rs 530 crore, a year on year growth of four per cent while Indian income stood at Rs 1330 crore registering a growth of 15 per cent during the quarter.
With three per cent growth emerging markets reported Rs 1,190 crore.
Revenues from Pharmaceutical Services and Active Ingredients stood at Rs 770 crore (14 per cent Y-o-Y growth) during the first quarter.
Source: PTI
Read More On:
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- AvanceTechnologies
- 0.94 ( -4.08)
- 36935326
- Vodafone Idea L
- 7.88 ( -2.11)
- 35484083
- Srestha Finvest
- 0.68 (+ 3.03)
- 30298217
- ARC Finance
- 2.78 (+ 2.96)
- 16033600
- Suzlon Energy Ltd.
- 62.50 ( -6.49)
- 13725252
MORE NEWS
Flender India to Invest Further in Indian Market
Flender India, part of the Flender Group, plans to continue investing in the Indian...
Aditya Birla Group to Invest More in US -...
Aditya Birla Group Chairman Kumar Mangalam Birla says the group is looking to invest...
Multipolar World: Jaishankar on Investment Targets
External Affairs Minister S Jaishankar discusses the shift towards a multipolar world...